Press release
Nonalcoholic Steatohepatitis (NASH) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Madrigal, Cirius, AstraZeneca, Ionis, Rivus Pharmaceuticals, Akero, Merck, Enanta, Hepion, GSK, Altimmune
"Nonalcoholic Steatohepatitis (NASH) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nonalcoholic Steatohepatitis Therapeutics Market.
The report provides a detailed description of the Nonalcoholic Steatohepatitis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Nonalcoholic Steatohepatitis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Nonalcoholic Steatohepatitis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nonalcoholic Steatohepatitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Nonalcoholic Steatohepatitis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Nonalcoholic Steatohepatitis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Nonalcoholic Steatohepatitis Therapeutics Domain:
https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Nonalcoholic Steatohepatitis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Nonalcoholic Steatohepatitis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Nonalcoholic Steatohepatitis (NASH) Therapeutics Analysis
There are approx. 130+ key companies which are developing therapies for Nonalcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Nonalcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.
Nonalcoholic Steatohepatitis (NASH) Companies in the Therapeutics Market Include:
Madrigal Pharmaceuticals, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and many others.
Emerging and Marketed Nonalcoholic Steatohepatitis (NASH) Therapies Covered in the Report Include:
• MSDC-0602K: Cirius Therapeutics
• ION224: Ionis Pharmaceuticals
• HU 6: Rivus Pharmaceuticals
• HTD 1801: HighTide Biopharma
• EDP-305: Enanta Pharmaceuticals
• Resmetirom: Madrigal Pharmaceuticals
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Nonalcoholic Steatohepatitis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Nonalcoholic Steatohepatitis Current Treatment Patterns
4. Nonalcoholic Steatohepatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Nonalcoholic Steatohepatitis Late-Stage Products (Phase-III)
7. Nonalcoholic Steatohepatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Nonalcoholic Steatohepatitis Discontinued Products
13. Nonalcoholic Steatohepatitis Product Profiles
14. Nonalcoholic Steatohepatitis Companies
15. Nonalcoholic Steatohepatitis Drugs
16. Dormant and Discontinued Products
17. Nonalcoholic Steatohepatitis Unmet Needs
18. Nonalcoholic Steatohepatitis Future Perspectives
19. Nonalcoholic Steatohepatitis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Madrigal, Cirius, AstraZeneca, Ionis, Rivus Pharmaceuticals, Akero, Merck, Enanta, Hepion, GSK, Altimmune here
News-ID: 3105100 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Nonalcoholic
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Drinking Nonalcoholic Beer Market Size 2024 to 2031.
Market Overview and Report Coverage
Drinking nonalcoholic beer is a type of beverage that has gained popularity as a healthier alternative to traditional beer. It contains little to no alcohol, making it suitable for individuals looking to enjoy the taste of beer without the effects of alcohol. The market for drinking nonalcoholic beer is steadily growing, with a projected CAGR of 6.00% during the forecasted period.
The future outlook of…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Nonalcoholic Steatohepatitis Therapeutics Market - Current status and future tre …
The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likely…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
Global Nonalcoholic Steatohepatitis Therapeutics Market
Nonalcoholic Steatohepatitis (NASH), also called the ‘silent disease,’ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure this…
